Loading patent…
AssigneeLynthera Corporation
InventorsArthur Jing-Min Yang, Naiping Hu, Roman C. Domszy, Cesar Torres Luna, Jeffry C. Yang
Estimating the term…
The present invention relates to a drug-eluting nanoengineered medical implant/contact device. The device comprises a nanocomposite and a drug, wherein the nanocomposite comprises hydrophilic polymer domains, hydrophobic polymer domains, water pores, and boundary charged double layers; wherein when the drug is hydrophilic, at least 80% of the drug partitions in the boundary charged double layers formed at the boundary interface of the hydrophilic polymer domains and water pores, and when the drug is hydrophobic, at least 80% of the dmg partitions in the boundary charged double layers formed at the boundary interface of the hydrophobic polymer domains and water pores. The device is configured to sustain the release of the drug at high precision and long duration.
A medical device comprising a nanocomposite and a drug, wherein the nanocomposite comprises hydrophilic polymer domains, hydrophobic polymer domains, water pores, and boundary charged double layers;
A medical device comprising a nanocomposite and a drug, wherein the nanocomposite comprises hydrophilic polymer domains, water pores, and boundary charged double layers, and at least 80% of the drug partitions in the boundary charged double layers formed at the boundary interface of the hydrophilic polymer domains and water pores.
A method for preparing a nanocomposite comprising hydrophilic polymer domains, hydrophobic polymer domains, water pores, and boundary charged double layers, comprises the steps of:
A method for preparing a nanocomposite comprising hydrophilic polymer domains, water pores, and boundary charged double layers, comprises the steps of:
Dependencies are inferred from the claim text.